Boston Scientific Corporation (NYSE:BSX) is included in our list of the best low-risk high-reward stocks<\/strong>.<\/p>\n As part of the firm\u2019s Q1 preview for medical technology and life science tools firms, Evercore ISI analyst Vijay Kumar reduced the firm\u2019s price target on Boston Scientific Corporation (NYSE:BSX) to $80 from $96 on April 6, 2026, while\u00a0maintaining\u00a0an \u201cOutperform\u201d rating.<\/p>\n On March 30, 2026, following the release of the firm\u2019s clinical trial data, RBC Capital reaffirmed an \u201cOutperform\u201d rating and a $115 price target for Boston Scientific. The firm expects 30% year-over-year growth in 2026, 10 percentage points higher than management guidance. Thus, Boston Scientific remains a good stock to buy.<\/p>\n Meanwhile, the company\u2019s\u00a0AsurysTM\u00a0Fluid Management System came into the spotlight recently.<\/p>\n The system, intended to enhance irrigation and regulate intrarenal pressure during urologic procedures like ureteroscopy, received 510(k) clearance from the U.S. Food and Drug Administration. Boston Scientific Corporation (NYSE:BSX) announced this on the same day as RBC Capital\u2019s update.<\/p>\n Based on Boston Scientific Corporation (NYSE:BSX)\u2019s pressure data, the system may control fluid flow in real time, thereby reducing problems and enhancing workflow efficiency and physician visualization. It also allows scope-based irrigation control and integrated pressure monitoring when used with the\u00a0LithoVue\u00a0Elite ureteroscope.<\/p>\n Despite more cautious near-term analyst views, the launch expands Boston Scientific\u2019s\u00a0StoneSmart\u00a0portfolio.<\/p>\n Boston Scientific Corporation (NYSE:BSX) is a global medical technology leader that develops, manufactures, and markets less-invasive medical devices used in interventional specialties, including cardiology, peripheral interventions, electrophysiology, endoscopy, and urology. Their products, such as stents, pacemakers, and imaging systems, are used by healthcare professionals worldwide to diagnose and treat various diseases.<\/p>\n While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/strong>.<\/p>\n<\/div>\n<\/div>